

General Information

Name: Dr. med. Jan Krönke
Date of Birth: 05.05.1979
Gender: Male
Address: Department of Internal Medicine III, Ulm University
Albert-Einstein-Allee 23, 89081 Ulm, Germany
Phone: +49 731 500 45718
E-Mail: jan.kroenke@uni-ulm.de
Current Position: Emmy-Noether Group Leader
Children: 2

Academic Education

1999-2006 Medical School, Ruprecht-Karls-University Heidelberg, Germany

Academic Degrees

06/2006 Medical Thesis (Molecular Virology, University of Heidelberg, Germany), grade *summa cum laude*
06/2006 Medical Exam and Approbation, Ruprecht-Karls-University Heidelberg, Germany
1998 Abitur (High school degree), Theodor-Heuss-Gymnasium, Göttingen, Germany

Professional Experience

Since 01/2015 Emmy Noether Research Group Leader (DFG)
05/2014-04/2015 Physician-Scientist fellowship (Else-Kröner Fresenius Kolleg Ulm), University Hospital of Ulm, Department of Internal Medicine III
01/2011-04/2014 Research Fellow at the Brigham and Women's Hospital/ Harvard Medical School, Laboratory of Prof. Dr. Benjamin L. Ebert, MD/PhD (DFG Research Fellowship)
06/2007-01/2011 Research Fellow at the University Hospital of Ulm, Department of Internal Medicine III, Laboratory of Prof. Dr. Konstanze Döhner
06/2006-01/2011 Residency in Internal Medicine and Hematology/Oncology at the University Hospital of Ulm, Department of Internal Medicine III (Director: Prof. Dr. Hartmut Döhner)
09/2002-05/2004 Doctoral student at the Ruprecht-Karls-University Heidelberg, Molecular Virology, Laboratory of Prof. Dr. Ralf Bartenschlager

Miscellaneous

Awards / Honors / Positions:

02/2015 Franziska-Kolb Award for Leukemia Research
Since 01/2015 Emmy Noether Research Program (DFG Kr3886/2-1)
05/2014-05/2015 Physician Scientist Fellowship, Else-Kröner Forschungs-kolleg,
01/2011-01/2014 Research Fellowship, Deutsche Forschungsgemeinschaft (DFG Kr3886/1-1)

Publications

1. Heuser M, Meggendorfer M, Cruz MM, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Guterthum A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. **Leukemia**. 2015 Sep;29(9):1942-5.
2. Krönke J*, Fink EC*, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL. Lenalidomide induces ubiquitination and degradation of casein kinase 1A1 in del(5q) MDS. **Nature**. 2015 Jul 9;523(7559):183-8. *contributed equally
3. Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. **Science**. 2014;343(6168):301-5.
4. Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MW, Rücker FG, Holzmann K, Paschka P, Kapp-Schwörer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk RF, Döhner H, Döhner K. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. **Blood**. 2013;122(1):100-8.
5. Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, Fries T, Krönke J, Kühn MW, Paschka P, Kayser S, Wolf S, Gaidzik VI, Schlenk RF, Rücker FG, Döhner H, Lottaz C, Döhner K, Bullinger L. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. **Blood**. 2012;120(18):e83-92.
6. Kühn MW, Radtke I, Bullinger L, Goorha S, Cheng J, Edelmann J, Gohlke J, Su X, Paschka P, Pounds S, Krauter J, Ganser A, Quessar A, Ribeiro R, Gaidzik VI, Shurtleff S, Krönke J, Holzmann K, Ma J, Schlenk RF, Rubnitz JE, Döhner K, Döhner H, Downing JR. High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. **Blood**. 2012;119(10):e67-75.
7. Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. **J Clin Oncol**. 2011;29(19):2709-16.
8. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. **J Clin Oncol**. 2010;28(22):3636-43.
9. Bullinger L*, Krönke J*, Schön C*, Radtke I, Urlbauer K, Botzenhardt U, Gaidzik V, Carió A, Senger C, Schlenk RF, Downing JR, Holzmann K, Döhner K, Döhner H. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. **Leukemia**. 2010;24(2):438-49. *equal contribution
10. Krönke J, Kittler R, Buchholz F, Windisch MP, Pietschmann T, Bartenschlager R, Frese M. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. **J Virol**. 2004;78(7):3436-46.

Patents

61/902.066 Prediction of therapeutic response to lenalidomide and related compounds,
Pending